Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature

Kaçar, Nida; Balcı, Didem Didar; Doğan, Sinan; Türkmen, Mutlu; Gönülal, Melis; Çınar, Gökhan

doi:10.12932/ap-241021-1259

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its effectiveness has been widely reported by clinical trials and real-life experiences. [75][76][77][78][79][80] In particular, to confirm the crucial role of IL-17A in psoriasis, two double-blind, 52week clinical, randomized, phase 3 trials which evaluated the efficacy and safety of secukinumab in patients with moderateto-severe plaque psoriasis were conducted. 81 The ERASURE (NCT01365455) (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) study included 738 adults with moderate-to-severe plaque psoriasis who were randomized 1:1:1 to receive subcutaneous secukinumab at a dose of 300 mg or 150 mg (once a week for 5 weeks, later Q4W), or placebo.…”

Section: Secukinumabmentioning

confidence: 99%

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio,

Martora,

Lauletta

et al. 2024

CCID

View full text Add to dashboard Cite

Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing the pivotal role of this axis has facilitated the development of selective and effective biological drugs, such as anti-IL17 and anti-IL23 monoclonal antibodies. These drugs aim to achieve the complete or near-complete disappearance of psoriatic lesions, as indicated by PASI100 and PASI90 responses, respectively. In this context, the aim of our review was to delve into the functioning of the IL-23/Th17 axis, its dysregulation in psoriasis pathogenesis, and the therapeutic potential of its inhibition. Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have been approved. All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics’ profile, in order to administer the right drug for the right patients at the right moment.

show abstract

Section: Secukinumabmentioning

confidence: 99%

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio,

Martora,

Lauletta

et al. 2024

CCID

View full text Add to dashboard Cite

show abstract

“…For example, secukinumab is proved effective for treating plaque psoriasis, and real-world studies demonstrate its effectiveness and long-term efficacy in managing this condition. 4 , 5 Real-world studies can significantly inform dermatological decision-making processes. However, real-world studies on secukinumab use in treating EP are scarce.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

Lu¹,

Wang²

2023

CCID

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare and severe type of psoriasis. Common systemic therapies for children with EP include treatment with glucocorticoids, cyclosporine, acitretin, and methotrexate. Although these drugs are effective, they may cause serious side effects to children. Secukinumab has recently demonstrated efficacy in treating plaque psoriasis, but its efficacy in EP children remains unknown. We report a case of a seven-year-old patient who transitioned from generalized pustular psoriasis (GPP) to EP after routine systemic drug treatment. The patient was then treated with secukinumab. The patient’s condition improved noticeably within 48 hours after the first injection. After the fifth injection, she almost completely cleared her skin lesions and achieved Psoriasis Area and Severity Index 90 (PASI 90) scores. During this period, she experienced only one respiratory infection. She completed all 11 doses of secukinumab by October 14, 2022, with no new rash (PASI 100) and no adverse drug reactions. Follow-up observation on March 15, 2023, showed no new rash (PASI 100) and no adverse reactions after medication withdrawal. This case suggests that it may also be effective in treating children with EP.

show abstract

Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature

Cited by 2 publications

References 0 publications

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report

Contact Info

Product

Resources

About